We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy

Product News   Oct 23, 2018

 
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy
FURTHER INFORMATION
 
 
 

Related Product News

Tumor Regression with New Antibody-Drug Conjugate

Product News

Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), has announced the first data on its lead ADC, IKS01.

READ MORE

Compact and Efficient Hematology Analysis

Product News

Diatron, provider of hematology and clinical chemistry analyzers, will exhibit its new hematology analyzer for the first time at Medica 2019.

READ MORE

Advancing Cancer Therapy With Exosome Isolation and Detection Kits

Product News

AMSBIO have introduced a new range of reagents designed for researchers investigating targeted cancer therapy.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE